Medscape warns clinicians on gray-market retatrutide use
The commentary recounts an after-hours call involving a patient using the unapproved triple agonist bought outside the regulated supply chain.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 9 14:38 ETSource: Medscape
The wire
- 01Medscape published a clinician account warning about patients self-sourcing retatrutide, an investigational triple incretin agonist not approved or marketed by any manufacturer.
- 02Prescribers and pharmacists are increasingly fielding questions from patients using research-grade incretins obtained online, outside pharmacy oversight and without dose verification.
- 03The piece is a narrative clinical commentary rather than new data; purity, dosing and adverse-event rates for gray-market retatrutide remain undocumented.
From the source
Read at medscape.comGray-Market Retatrutide: A Midnight Call, a Warning
